Retatrutide Just Entered the Sleep Apnea Conversation
Two Phase 3 trials in the New England Journal of Medicine asked whether a molecule could move the sleep apnea number. For retatrutide, the answer was yes — with the caveats doing as much work as the headline.
What a COA Actually Proves — and What It Doesn’t
A certificate of analysis is the most quoted document in the peptide world — and the least read. Most buyers glance at one number, the purity percentage, and stop. That number is real. It is also only one line of the report, and it answers exactly one question. Here is what each line actually proves, […]
The Gray Market Is Booming. The Testing Isn’t.
The gray market for peptides is having its biggest year ever — and its least careful one. Chainalysis, the blockchain-analysis firm, tracked cryptocurrency payments to gray-market peptide vendors and found about $32 million flowed in during the first quarter of 2026 alone — up roughly 159% from the quarter before. The market is on pace […]
The Peptide Harm Stories Deserve a Hearing — Not a Shrug
UPDATE — OCT 13 CBS News reported today that the FDA received two death reports in recent months involving products claiming to be retatrutide — one in July, one in September, both cardiac arrest, both tied to black-market supply, one involving vials a nurse sold from an online vendor. The FDA has not verified either […]
The Mitochondrial Peptide With Two Cancer Stories
MOTS-c is one of the most talked-about peptides in my world — a 16-amino-acid fragment encoded in mitochondrial DNA, studied as an “exercise mimetic” for metabolism. It’s also one of my five priority products at Atlas, so you should know exactly where I stand on the hardest question about it: what does the cancer research […]
A Billion-Dollar Fight Over One Word: “Alpha”
Retatrutide is the most effective weight-loss drug ever tested — 28.3% average body-weight loss in Lilly’s Phase 3 trial, numbers in bariatric-surgery territory. Right now, Eli Lilly is in federal court fighting the FDA over it. Not over whether it works. Over what it is. The whole case turns on one word: alpha. ATLAS PERFORMANCE Get […]
HHS Wants Pharmacies to Compound BPC-157 Again — Here’s What’s Actually Happening
On October 7, the Washington Post reported that federal health officials are preparing a stopgap order that would let state-licensed compounding pharmacies temporarily dispense certain unapproved peptides — including names this blog’s readers know well: BPC-157, TB-500, KPV, and MOTS-c. Here’s the honest breakdown: what we know, what we don’t, and why it matters. ATLAS PERFORMANCE […]
Retatrutide: The Most Powerful Obesity Drug Ever Tested Just Published Its Pivotal Trial
On September 29, the New England Journal of Medicine published TRIUMPH-1 — the pivotal Phase 3 trial for retatrutide, Eli Lilly’s triple-agonist obesity drug. The numbers are the largest ever recorded for a weight-loss medication. What it is Retatrutide (developed as LY3437943) hits three receptors at once: GIP, GLP-1, and glucagon. Semaglutide hits one. Tirzepatide […]